How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

184,068 results for

Screening Test

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy Full Text available with Trip Pro

Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline | The BMJ Intended for healthcare professionals Username * Password * Edition: Search form Search Search Colorectal cancer... Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline (Published 02 October 2019) Cite (...) the benefits and harms of different screening tests for their individual situation. Faecal testing with a faecal immunochemical test (FIT) every year Faecal testing with a faecal immunochemical test (FIT) every two years Endoscopic examination of only the lower part of the colon Endoscopic examination of the entire colon Favours no screening Favours screening Colonoscopy offered if FIT or sigmoidoscopy positive People with an estimated 15 year risk of colorectal cancer below 3% We suggest screening

2019 BMJ Rapid Recommendations

2. Molecular and antibody point-of-care tests to support the screening, diagnosis and monitoring of COVID-19 Full Text available with Trip Pro

Molecular and antibody point-of-care tests to support the screening, diagnosis and monitoring of COVID-19 Molecular and antibody point-of-care tests to support the screening, diagnosis and monitoring of COVID-19 - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Molecular and antibody point-of-care tests to support the screening, diagnosis and monitoring of COVID-19 April 7, 2020 Kile Green 1 , Sara (...) and G (IgM and IgG). IgM is the largest immunoglobulin, and is the first to appear after initial exposure to an antigen. IgG is the most common antibody found in the body, which will appear later but will be generated in abundance. These tests can determine whether a patient has previously been infected with coronavirus, as they will stay positive after active infection has gone. Currently, serological testing is not routinely offered as part of the screening or diagnosis of COVID-19

2020 Oxford COVID-19 Evidence Service

3. What tests could potentially be used for the screening, diagnosis and monitoring of COVID-19 and what are their advantages and disadvantages?

What tests could potentially be used for the screening, diagnosis and monitoring of COVID-19 and what are their advantages and disadvantages? What tests could potentially be used for the screening, diagnosis and monitoring of COVID-19 and what are their advantages and disadvantages? - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website What tests could potentially be used for the screening, diagnosis (...) , York, YO19 6FD 4 Institute of Applied Health Research University of Birmingham B15 2TT VERDICT Many diagnostic tests for coronavirus disease 2019 (COVID-19) are available so far, with more gaining emergency approval every day. These tests are largely based on four different techniques, 1) reverse transcription polymerase chain reaction (RT-PCR) – the current standard test for COVID-19, 2) loop-mediated isothermal amplification (LAMP) – a simple, but less developed testing method, 3) lateral flow

2020 Oxford COVID-19 Evidence Service

4. Screening for asymptomatic bacteriuria within the framework of the German maternity guidelines, under special consideration of test methods - Addendum to Commission S13-02

Screening for asymptomatic bacteriuria within the framework of the German maternity guidelines, under special consideration of test methods - Addendum to Commission S13-02 1 Translation of the executive summary of the addendum S16-01 Screening auf asymptomatische Bakteriurie im Rahmen der Mutterschafts-Richtlinien unter besonderer Berücksichtigung der Testmethoden – Addendum zum Auftrag S13-02 (Version 1.0; Status: 19 October 2016). Please note: This document was translated by an external (...) translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. S16-01 Screening for asymptomatic bacteriuria within the framework of the German maternity guidelines, under special consideration of test methods – Addendum to Commission S13-02 1 Extract of addendum S16-01 Version 1.0 Screening for bacteriuria in pregnant women 19 October 2016 Institute for Quality

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

5. Prostate cancer screening with prostate-specific antigen (PSA) test Full Text available with Trip Pro

Prostate cancer screening with prostate-specific antigen (PSA) test Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline | The BMJ Intended for healthcare professionals Username * Password * Edition: Search form Search Search Prostate cancer... Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline CC BY NC Open access (Published 05 September 2018) Cite this as: BMJ 2018;362:k3581 Population Diagnostic (...) therapy Can be followed by radical treatment Men without a previous diagnosis of prostate cancer considering screening Comparison or Screening No screening Screening No screening Using prostate- specific antigen testing We suggest against systematic PSA-based screening for prostate cancer. Either option is reasonable. Shared decision making is needed for men considering screening. More details Strong All or nearly all informed people would likely want this option. Benefits outweigh harms for almost

2018 BMJ Rapid Recommendations

6. Urinary Dipstick Testing for Bladder Cancer Screening: Diagnostic Accuracy, Clinical Effectiveness and Guidelines

Urinary Dipstick Testing for Bladder Cancer Screening: Diagnostic Accuracy, Clinical Effectiveness and Guidelines Urinary Dipstick Testing for Bladder Cancer Screening: Diagnostic Accuracy, Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Urinary Dipstick Testing for Bladder Cancer Screening: Diagnostic Accuracy, Clinical Effectiveness and Guidelines Urinary Dipstick Testing for Bladder Cancer Screening: Diagnostic Accuracy, Clinical Effectiveness and Guidelines (...) Last updated: April 1, 2019 Project Number: RB1320-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the diagnostic accuracy of urinary dipstick testing for bladder cancer screening in asymptomatic adult patients with microscopic hematuria? What is the clinical effectiveness of urinary dipstick testing for bladder cancer screening in asymptomatic adult patients? What are the evidence-based guidelines regarding the use

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update

HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update | CADTH.ca Find the information you need HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update HPV Self-Sampling for Primary Cervical Cancer Screening: A Review (...) of Diagnostic Test Accuracy and Clinical Evidence – An Update Last updated: May 30, 2019 Project Number: RC1124-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the diagnostic test accuracy of self-sampled HPV tests compared with clinician-sampled HPV tests or cytology for asymptomatic cervical cancer screening? What is the clinical evidence regarding the agreement or concordance of self-sampled HPV tests and clinician

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Cervical screening: acceptable HPV tests

Cervical screening: acceptable HPV tests Cervical screening: acceptable HPV tests - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Cervical screening: acceptable HPV tests Updated 18 June 2019 Contents © Crown copyright 2019 This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit or write to the Information Policy Team (...) , The National Archives, Kew, London TW9 4DU, or email: . Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. This publication is available at https://www.gov.uk/government/publications/cervical-screening-acceptable-hpv-tests/cervical-screening-acceptable-hpv-tests 1. Introduction The following high risk human papillomavirus ( has published the contract prices for test kits in an NHS Framework. Only test kits detailed

2019 Public Health England

9. Covid-19: Recommendations for GDM screening and oral glucose tolerance test (OGTT) during pregnancy and postpartum

Covid-19: Recommendations for GDM screening and oral glucose tolerance test (OGTT) during pregnancy and postpartum Translating evidence into best clinical practice Queensland Health NOTICE OF UPDATE DURING COVID-19 PANDEMIC DATE 14 April 2020 TOPIC Recommendations for GDM screening and oral glucose tolerance test (OGTT) during pregnancy and postpartum APPLIES TO All pregnant and postnatal women irrespective of COVID-19 status RATIONALE During the COVID-19 pandemic • Supports social distancing (...) . there is no requirement to alter request for OGTT if this has already been recommended to the woman) SECTION OF GUIDELINE AFFECTED BY UPDATE • Flowchart: Screening and diagnosis of GDM (updated flow available) • Section 2.5 Testing for GDM (updated) • Section 6.3 Discharge planning (updated) UPDATED RECOMMENDATION All women (irrespective of COVID-19 status) • If clinical features of concern emerge during pregnancy (e.g. macrosomia, fetus accelerating through centiles, other concerns), then recommend usual screening

2020 Queensland Health

10. ASCCP Interim Guidance for Timing of Diagnostic and Treatment Procedures for Patients with Abnormal Cervical Screening Tests

ASCCP Interim Guidance for Timing of Diagnostic and Treatment Procedures for Patients with Abnormal Cervical Screening Tests COVID-19 - ASCCP ');//]]> Register Today! Virtual Conference Starting Soon. Colposcopy Standards Recommendations Recommendations on New Standards of Colposcopy Practice Webinars Live and On-Demand Member Resources ASCCP Interim Guidance for Timing of Diagnostic and Treatment Procedures for Patients with Abnormal Cervical Screening Tests March 19, 2020 - In light (...) of the current unprecedented COVID-19 pandemic, and in settings where all non-essential medical office visits and elective procedures have been suspended, ASCCP recommends the following: Individuals with low-grade cervical cancer screening tests may have postponement of diagnostic evaluations up to 6-12 months. Individuals with high-grade cervical cancer screening tests should have documented attempts to contact and diagnostic evaluation scheduled within 3 months. Individuals with high-grade cervical disease

2020 American Society for Clinical Pathology

11. Legal Considerations in Genetic Screening and Testing: Three Case Studies

Legal Considerations in Genetic Screening and Testing: Three Case Studies Legal Considerations in Genetic Screening and Testing: Three Case Studies | ACOG Clinical Guidance Journals & Publications Patient Education Topics Featured Clinical Topics Hi, Featured Clinical Topics Clinical Guidance Legal Considerations in Genetic Screening and Testing: Three Case Studies Committee Opinion Number 805 April 2020 Jump to Resources Share By reading this page you agree to ACOG's Terms and Conditions (...) and Gynecologists’ documents, including Committee Opinion No. 777 Sexual Assault and Committee Opinion No. 518 Intimate Partner Violence for further resources. Adequate pretest counseling and screening, including an extensive family history, may help to avoid discovering information unexpectedly. Patients should be made aware that information about blood relatedness may be revealed by some prenatal genetic tests. Because of the complex genetic, ethical, and legal implications of discovering such information

2020 American College of Obstetricians and Gynecologists

12. AIM Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis

AIM Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis Appropriate.Safe.Affordable © 2019 AIM Specialty Health 2068-0319 Clinical Appropriateness Guidelines Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis EFFECTIVE MARCH 3, 2020 PROPRIETARY Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2019 Informed Medical Decisions, Inc. All Rights Reserved. 2 Table of Contents (...) Scope 3 Appropriate Use Criteria 3 Carrier Screening for Familial Disease 3 Fragile X 3 Carrier Screening for Common and Ethnic Genetic Diseases 3 Cystic Fibrosis 3 Spinal Muscular Atrophy 4 Hemoglobinopathies 4 Ashkenazi Jewish Carrier Screening 4 Other Ethnicities 5 Carrier Screening Not Clinically Appropriate 5 Preimplantation Genetic Screening and Diagnostic Testing of Embryos 5 Preimplantation Genetic Screening for Common Aneuploidy 6 Prenatal Cell-Free DNA Screening 6 Prenatal Molecular

2020 AIM Specialty Health

13. HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence

HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence | CADTH.ca Find the information you need HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical (...) Evidence Last updated: April 19, 2018 Project Number: RC0981-000 Product Line: Research Type: Other Diagnostics Report Type: Summary with Critical Appraisal Result type: Report Question What is the diagnostic test accuracy of self-sampled HPV tests compared with clinician-sampled HPV tests or cytology for asymptomatic cervical cancer screening? What is the clinical evidence regarding the agreement or concordance of self-sampled HPV tests and clinician-sampled HPV tests or cytology for asymptomatic

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

16. HPV Testing for Primary Cervical Cancer Screening

HPV Testing for Primary Cervical Cancer Screening HPV Testing for Primary Cervical Cancer Screening | CADTH.ca Find the information you need HPV Testing for Primary Cervical Cancer Screening HPV Testing for Primary Cervical Cancer Screening Published on: March 26, 2019 Project Number: OP0530-000 Product Line: Result type: Report Worldwide, cervical cancer is one of the most frequently diagnosed cancers; however, the incidence of cervical cancer has been decreasing in the past three decades (...) , largely due to routine screening with cytology. HPV is the major risk factor for the development of cervical cancer, with 99% of cervical cancer being associated with HPV. It is one of the most common sexually transmitted infections in the world and about three out of every four sexually active Canadians will have at least one HPV infection at some point in their lives. In view of the anticipated higher sensitivity of HPV testing, some experts and stakeholders have called for HPV testing to be used

2019 CADTH - Optimal Use

17. AIM Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis

AIM Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis Appropriate.Safe.Affordable © 2019 AIM Specialty Health 2068-0319b Clinical Appropriateness Guidelines Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis EFFECTIVE MARCH 31, 2019 PROPRIETARY Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2019 Informed Medical Decisions, Inc. All Rights Reserved. 2 Table (...) of Contents Scope 3 Appropriate Use Criteria 3 Carrier Screening for Familial Disease 3 Fragile X 3 Carrier Screening for Common and Ethnic Genetic Diseases 3 Cystic Fibrosis 3 Spinal Muscular Atrophy 4 Hemoglobinopathies 4 Ashkenazi Jewish Carrier Screening 4 Other Ethnicities 5 Carrier Screening Not Clinically Appropriate 5 Preimplantation Genetic Screening and Diagnostic Testing of Embryos 5 Preimplantation Genetic Screening for Common Aneuploidy 6 Prenatal Cell-Free DNA Screening 6 Prenatal Molecular

2019 AIM Specialty Health

18. Screening for colorectal cancer-where does the fit-DNA test fit?

Screening for colorectal cancer-where does the fit-DNA test fit? Screening for Colorectal cancer-Where does the FIT-DNA test fit? – Clinical Correlations Search Screening for Colorectal cancer-Where does the FIT-DNA test fit? February 21, 2019 6 min read . Almost all CRC develops from precancerous polyps, and with appropriate colonoscopy screening most polyps can be detected and removed before they transform into cancer. Simply put, CRC screening saves lives. ; however, over 40% of . Perhaps (...) some of this resistance is due to the invasive nature of the mostcommon testing procedure, colonoscopy. Whatever the cause, this avoidance of testing has contributed to as many as . For many years, the USPTSF has recommended four different CRC screening modalities. Some are more invasive and off-putting than others. Colonoscopy, the gold standard, has the highest sensitivity and specificity for cancer detection but requires patients to forego solid food for a day and drink large volumes

2019 Clinical Correlations

19. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors Full Text available with Trip Pro

2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors 2019 ASCCP Risk-Based Management Consensus Guidelines for Ab... : Journal of Lower Genital Tract Disease ')} You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Your account has been temporarily locked Your account has been temporarily locked due to incorrect sign in attempts and will be automatically (...) available cervical screening strategies: primary human papillomavirus (HPV) screening, cotesting with HPV testing and cervical cytology , and cervical cytology alone. New data indicate that a patient's risk of developing cervical precancer or cancer can be estimated using current screening test results and previous screening test and biopsy results, while considering personal factors such as age and immunosuppression. Routine screening applies only to asymptomatic individuals who do not require

2019 American Society for Clinical Pathology

20. Longer screening intervals are recommended following a negative HPV test in primary cervical screening

Longer screening intervals are recommended following a negative HPV test in primary cervical screening Longer screening intervals are recommended following a negative HPV test in primary cervical screening | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Longer screening intervals are recommended following a negative HPV test in primary cervical screening Article Text Commentary Primary care Longer screening intervals are recommended

2017 Evidence-Based Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>